IBTK and diffuse large B-cell lymphoma: Furthermore, venetoclax resistance in DLBCL could be circumvented by inhibiting transcription with CDK7/9i, BCR signaling with BTKi, SYKi, or PI3Ki, and deacetylation with class I HDACi.